← Back to Search

Radiation Therapy

1 for Amyotrophic Lateral Sclerosis

Phase 1
Waitlist Available
Led By Ken Nedd, M.D.
Research Sponsored by GAAD Medical Research Institute Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with ALS
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

Amyotrophic Lateral Sclerosis (ALS, sometimes called Lou Gehrig's s Disease, or Maladie de Charcot) is a progressive, usually fatal, neurodegenerative disease caused by the degeneration of motor neurons, the nerve cells in the central nervous system that control voluntary muscle movement. This study will investigate the use of far infrared radiation for the control, management and treatment of ALS.

Eligible Conditions
  • Amyotrophic Lateral Sclerosis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Therapy for ALS
Secondary outcome measures
Rehabilitation of ALS patients

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment2 Interventions
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Far infrared radiation
2019
N/A
~210

Find a Location

Who is running the clinical trial?

GAAD Medical Research Institute Inc.Lead Sponsor
21 Previous Clinical Trials
88 Total Patients Enrolled
Ken Nedd, M.D.Principal InvestigatorGAAD Medical Research Institute Inc.
19 Previous Clinical Trials
86 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~0 spots leftby Mar 2025